Glioblastoma Clinical Trials

284 recruiting

Frequently Asked Questions

Common questions about Glioblastoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 284 trials

Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled1 locationNCT07326566
Recruiting
Phase 1Phase 2

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

GlioblastomaGliomaMedulloblastoma+1 more
National Cancer Institute (NCI)146 enrolled1 locationNCT06161519
Recruiting
Phase 2

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

GlioblastomaGBM
Alpheus Medical, Inc.103 enrolled8 locationsNCT07225621
Recruiting
Phase 2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent GlioblastomaProgressive Glioblastoma
National Cancer Institute (NCI)184 enrolled317 locationsNCT06325683
Recruiting
Phase 1

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Pancreatic CancerLung CancerColon Cancer+3 more
RasCal Therapeutics, Inc.134 enrolled3 locationsNCT04678648
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-MutantRecurrent Adult Diffuse Midline Glioma, H3 K27-Mutant+4 more
National Cancer Institute (NCI)30 enrolled41 locationsNCT06860594
Recruiting
Phase 1

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

GlioblastomaGliosarcoma
Memorial Sloan Kettering Cancer Center60 enrolled9 locationsNCT06934889
Recruiting
Phase 3

Treatment Intensification With Temozolomide in Adults With a Glioblastoma

Glioblastoma
Centre Oscar Lambret486 enrolled19 locationsNCT03663725
Recruiting
Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

Central Nervous System TumorGlioblastomaCNS Tumor+5 more
Sabine Mueller, MD, PhD208 enrolled6 locationsNCT04732065
Recruiting
Phase 1Phase 2

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

Breast CancerLung CancersOvarian Cancer+4 more
Filamon LTD80 enrolled3 locationsNCT06926075
Recruiting
Phase 1

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

GliomaRecurrent GlioblastomaAstrocytoma
National Cancer Institute (NCI)28 enrolled1 locationNCT06344130
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07480941
Recruiting
Phase 1

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

GlioblastomaEGFR Gene MutationMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD20 enrolled1 locationNCT06186401
Recruiting
Phase 2

Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

Glioblastoma
Sunnybrook Health Sciences Centre118 enrolled1 locationNCT07476794
Recruiting
Phase 2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
BioNTech SE75 enrolled1 locationNCT07297212
Recruiting
Phase 3

Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

GlioblastomaNeoplastic DiseaseGlioblastoma (GBM)+3 more
Telix Pharmaceuticals (Innovations) Pty Limited50 enrolled4 locationsNCT07100730
Recruiting
Phase 3

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Glioblastoma
NovoCure GmbH741 enrolled82 locationsNCT06556563
Recruiting
Phase 1

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Glioblastoma
Dana-Farber Cancer Institute56 enrolled2 locationsNCT02287428
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899